These results highlight the immunological roles of DOCK2 in complications of COVID-19 such as type I IFN immunity and chemotaxis dysregulation, as exemplified by patients with congenital impairment in type I IFN immunity31. The gene discussed is DOCK2; the disease is COVID-19.